• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Dosing schedules for VENCLYXTO combination regimens

      VENCLYXTO combinations are designed to give your CLL patients a chance to take their life back with a fixed treatment duration.1-5

      The 5-week dose-titration schedule is designed to gradually reduce tumour burden (debulk) and decrease the risk of TLS. 1

      Ven+O: Designed to be completed in 1 year in 1L CLL1

      *Each cycle is 28 days.
      †Administered orally. Start the 5-week VENCLYXTO dose titration schedule on cycle 1 day 22.
      ‡100 mg on cycle 1 day 1, followed by 900 mg, which may be administered on day 1 or 2.
      IV = intravenous; Ven+O= VENCLYXTO + obinutuzumab.

      Ven+R: Designed to be completed in 2 years following the 5 week dose titration in R/R CLL patients1

      *Each cycle is 28 days.
      †Administered orally.
      IV = intravenous; Ven+R = VENCLYXTO + rituximab.


      * The modified dose should be continued for 1 week before increasing the dose.

      A larger dose reduction may occur at physicians discretion.

      Consider discontinuation of VENCLYXTO if patients have to be dose-reduced to less than 100 mg for more than two weeks.

      * The modified dose should be continued for 1 week before increasing the dose.


      CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

      References

      1. VENCLYXTO Summary of Product Characteristics.
      2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
      3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
      4. Leukaemia Care Living with Leukaemia 2018 Report https://media.leukaemiacare.org.uk/wp-content/uploads/Living-with-Leukaemia-2018-Full-Report_compressed.pdf (accessed December 2021).
      5. Al-Sawaf O et al. Am J Hematol. 2021; 96(9): 1112-19. doi: 10.1002/ajh.26260.

       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-210548. Date of preparation: December 2021.